The Novel AT2 Receptor Agonist β-Pro7-AngIII Exerts Cardiac and Renal Anti-Fibrotic and Anti-Inflammatory Effects in High Salt-Fed Mice

Yan Wang 1,2, Jonathan Yodgee 1,2, Mark Del Borgo 1,2, Iresha Spizzo 1,2, Levi Nguyen 1,2, Marie-Isabel Aguilar 1,3, Kate M. Denton 1,4, Christan S. Samuel 1,2 and Robert E. Widdop 1,2,*

1 Cardiovascular Disease Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia
2 Departments of Pharmacology, Monash University, Clayton, VIC 3800, Australia
3 Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia
4 Department of Physiology, Monash University, Clayton, VIC 3800, Australia
* Correspondence: robert.widdop@monash.edu

Abstract: A high salt (HS) diet is associated with an increased risk for cardiovascular diseases (CVDs) and fibrosis is a key contributor to the organ dysfunction involved in CVDs. The activation of the renin angiotensin type 2 receptor (AT2R) has been considered as organ protective in many CVDs. However, there are limited AT2R-selective agonists available. Our first reported β-substituted angiotensin III peptide, β-Pro7-AngIII, showed high selectivity for the AT2R. In the current study, we examine the potential anti-fibrotic and anti-inflammatory effects of this novel AT2R-selective peptide on HS-induced organ damage. FVB/N mice fed with a 5% HS diet for 8 weeks developed cardiac and renal fibrosis and inflammation, which were associated with increased TGF-β1 levels in heart, kidney and plasma. Four weeks’ treatment (from weeks 5–8) with β-Pro7-AngIII inhibited the HS-induced cardiac and renal fibrosis and inflammation. These protective effects were accompanied by reduced local and systemic TGF-β1 as well as reduced cardiac myofibroblast differentiation. Importantly, the anti-fibrotic and anti-inflammatory effects caused by β-Pro7-AngIII were attenuated by the AT2R antagonist PD123319. These results demonstrate, for the first time, the cardio- and reno-protective roles of the AT2R-selective β-Pro7-AngIII, highlighting it as an important therapeutic that can target the AT2R to treat end-organ damage.

Keywords: fibrosis; AT2 receptor; inflammation

1. Introduction

Cardiovascular diseases (CVDs) remain the leading cause of mortality and morbidity globally, which are often initiated by cardiac or renal insult and injury, that activates the innate immune system to trigger inflammatory responses for tissue repair [1,2]. Repetitive injury leads to dysregulated extracellular matrix (ECM) remodelling, including increased tissue (TGF)-β1-mediated myofibroblast differentiation and reduced collagen degradation [3–6], which all contribute to accumulated collagen in organs (e.g., the heart and kidneys), driving towards progressive cardiac and renal fibrosis, which eventually cause organ dysfunction [7].

Current frontline therapies for cardiovascular diseases are largely dependent on the blockade of the renin angiotensin system, including angiotensin type 1 receptor (AT1R) blockers and angiotensin-converting enzyme inhibitors (ACEi). However, their abilities to reduce organ damage are limited [8,9], highlighting the urgency of developing novel therapeutic treatments for end-organ damage, including fibrosis.

The angiotensin type 2 receptor (AT2R) is upregulated following cardiovascular injury in rodents [10–16] and well as in human cardiac biopsies [17–20]. The stimulation of the
AT2R has been shown to be cardio- and reno-protective in various animal models in the past decade [20–22]. However, there are limited AT2R-selective ligands that are currently available. To address this issue, our group has synthesized a library of AT2R-selective agonists based on the peptide sequence of AngIII peptide, which has a slightly higher affinity for the AT2R over the AT1R [23], using a β-amino acid substitution strategy [24]. We have recently reported that a single β-substitution to the amino acid proline in position 7 of Ang III (β-Pro7-AngIII) resulted in a more than 20,000-fold AT2R/AT1R selectivity, and this peptide evoked vasorelaxation in vitro and also reduced blood pressure in conscious spontaneous hypertensive rats (SHRs), which were blocked by the AT2R antagonist PD123319 [25]. More recently, we reported that β-Pro7-AngIII improved renal function by promoting renal vasodilation and natriuresis in normotensive rats, which were also blocked by PD123319 [26].

To date, the chronic effects of β-Pro7-AngIII have not been examined. On the basis of previous studies [21], we hypothesized that this peptide would exhibit anti-inflammatory and anti-fibrotic effects. To this end, we now report the effects of the novel highly selective AT2R agonist, β-Pro7-AngIII, on cardiac and renal inflammation and fibrosis following a high salt (HS) diet.

2. Results

2.1. Blood Pressure and Body Weight

After 8 weeks on a HS diet, the systolic blood pressure (SBP) was similar to that of NS-fed mice, and there was no significant effect of β-Pro7-AngIII on SBP (Figure S1). Cardiac hypertrophy, measured by the left ventricular weight (VW) to body weight (BW) ratio, was similar between groups: 3.74 ± 0.16 (NS); 4.10 ± 0.14 (HS); 4.00 ± 0.05 (HS+ β-Pro7-AngIII); 4.02 ± 0.16 (HS+ β-Pro7-AngIII+PD123319).

2.2. Cardiac and Renal Fibrosis

Cardiac and renal fibrosis were measured using picrosirius red staining to estimate collagen I and III [27] as well as by hydroxyproline for total collagen concentration [28]. HS increased cardiac and renal interstitial fibrosis by ~1.5 fold using both picrosirius red staining and hydroxyproline measurements (Figures 1 and 2). This HS-induced cardiac and renal fibrosis was inhibited by the novel AT2R-selective peptide, β-Pro7-AngIII (Figures 1 and 2). Importantly, the anti-fibrotic effects caused by β-Pro7-AngIII were abolished by the AT2R antagonist PD123319 using both fibrotic measurements (Figures 1 and 2).

![Figure 1. Cont.](image-url)
Figure 1. Representative (a) bright view and (b) polarized view for interstitial fibrosis sections stained with picrosirius red (indicated by red) in left ventricle (LV) obtained from male FVB/N mice fed on a normal salt (NS, 0.5% NaCl) diet or mice fed on a high salt (HS, 5% NaCl) diet in the presence or absence of β-Pro7-AngIII (0.1 mg/kg/day) +/- PD123319 (1 mg/kg/day). Scale bar for all images = 50 μm. (c) Group data of % area of interstitial fibrosis in LV sections. (d) Total tissue collagen measured by hydroxyproline assay in LV tissue from same animal groups in which picrosirius red staining was performed (n = 7–8 per group). All data are expressed as mean ± s.e.m. *p < 0.05, **p < 0.01 vs. sham; #p < 0.05, ##p < 0.01 vs. HS; &p < 0.05 vs. HS+ β-Pro7-AngIII, determined by One-Way ANOVA with Tukey correction for multiple comparisons.

Figure 2. (a) Representative images for interstitial fibrosis stained with picrosirius red (indicated by red) in kidney sections obtained from male FVB/N mice fed on a normal salt (NS, 0.5% NaCl) diet or mice fed on a high salt (HS, 5% NaCl) diet in the presence or absence of β-Pro7-AngIII (0.1 mg/kg/day) +/- PD123319 (1 mg/kg/day). Scale bar for all images = 50 μm. (b) Group data of % area of interstitial fibrosis in kidney sections. (c) Total tissue collagen measured by hydroxyproline assay in kidney tissue from same animal groups in which picrosirius red staining was performed (n = 7–8 per group). All data are expressed as mean ± s.e.m. ***p < 0.001 vs. sham; #p < 0.05, ###p < 0.001 vs. HS; &&p < 0.01 vs. HS+ β-Pro7-AngIII, determined by One-Way ANOVA with Tukey correction for multiple comparisons.
TGF-β1 is considered to be the major pro-fibrotic mediator for collagen synthesis and fibrosis development [3,4]. The HS diet increased tissue TGF-β1 levels, measured by immunofluorescence, in both the heart and kidney, which was attenuated by β-Pro7-AngIII whereas the co-administration of PD123319 inhibited the effects of β-Pro7-AngIII (Figure 3a,c and Figure 4a,b). Moreover, circulating TGF-β1 levels were significantly inhibited by β-Pro7-AngIII compared with the untreated HS group (Figure 4c).

Figure 3. Representative images for (a) TGF-β1 and (b) α-SMA in cardiac sections obtained from male FVB/N mice fed on a normal salt (NS, 0.5% NaCl) diet or mice fed on a high salt (HS, 5% NaCl) diet in the presence or absence of β-Pro7-AngIII (0.1 mg/kg/day) +/- PD123319 (1 mg/kg/day). Scale bar for all images = 50 µm. Group data of % area of (c) TGF-β1 and (d) α-SMA in cardiac sections (n = 7–8 per group). All data are expressed as mean ± s.e.m. ** p < 0.01 vs. sham; # p < 0.05, ## p < 0.01 vs. HS, determined by One-Way ANOVA with Tukey correction for multiple comparisons.

TGF-β1 promotes the differentiation of fibroblasts into myofibroblasts [5,6], which are the major cellular driver for collagen production [29–31]. The expression of α-smooth muscle actin (α-SMA) identifies the differentiated myofibroblasts [32,33]. Cardiac α-SMA immunofluorescence was elevated by a 2-fold increase by the HS diet, which was significantly inhibited by β-Pro7-AngIII in a PD123319-sensitive manner (Figure 3b,d).
Figure 4. (a) Representative images for TGF-β1 in kidney sections obtained from FVB/N male mice fed on a normal salt (NS, 0.5% NaCl) diet or mice fed on a high salt (HS, 5% NaCl) diet in the presence or absence of β-Pro7-AngIII (0.1 mg/kg/day) +/- PD123319 (1 mg/kg/day). Scale bar for all images = 50 μm. (b) Group data of % area of TGF-β1 in cardiac sections. (c) Plasma TGF-β1 levels (n = 7–8 per group). All data are expressed as mean ± s.e.m. * p < 0.05 vs. sham; # p < 0.05 vs. HS, determined by One-Way ANOVA with Tukey correction for multiple comparisons.

2.3. Cardiac and Renal Inflammation

Cardiac and renal phosphorylated (p)-IkBα was measured by immunofluorescence as a marker for NF-κB activity. In both the heart and kidney, HS significantly increased p-IkBα by ~1.5 fold (Figure 5a,c and Figure 6a,c). The HS-induced p-IkBα was attenuated by β-Pro7-AngIII in the heart and kidney, and these anti-inflammatory effects were inhibited by PD123319 (Figure 5a,c and Figure 6a,c).

The macrophage marker F4/80 was readily detected in the kidney but not the heart; the monocyte chemoattractant protein (MCP)-1 was therefore measured in the heart. HS increased renal F4/80 immunofluorescence ~2.5-fold (Figure 6b,d), while MCP-1 was modestly increased by HS in the heart (Figure 5b,d). Nevertheless, β-Pro7-AngIII significantly reduced cardiac MCP-1 and renal F4/80 levels whereas PD123319 inhibited the effects of β-Pro7-AngIII in these tissues (Figure 5d,b and Figure 6b,d).
Figure 5. Representative images for (a) p-IκB and (b) MCP-1 in LV sections obtained from male FVB/N mice fed on a normal salt (NS, 0.5% NaCl) diet or mice fed on a high salt (HS, 5% NaCl) diet in the presence or absence of β-Pro7-AngIII (0.1 mg/kg/day) +/- PD123319 (1 mg/kg/day). Scale bar for all images = 50 μm. Group data of % area of (c) p-IκB and (d) MCP-1 in LV sections from indicated groups (n = 4–6 per group). All data are expressed as mean ± s.e.m. * p < 0.05 vs. sham; ## p < 0.01 vs. HS; && p < 0.01 vs. HS+β-Pro7-AngIII, determined by One-Way ANOVA with Tukey correction for multiple comparisons.

Figure 6. Cont.
ANOVA with Tukey correction for multiple comparisons. Similarly, we found that a HS diet (5%) increased cardiac and renal interstitial peptide, at the dose that evoked anti-fibrotic and anti-inflammatory effects, did not affect p vs. sham; ## p<0.01 vs. HS; & & p < 0.01 vs. HS; & p < 0.05, && p < 0.01 vs. HS+ β- Pro7-AngIII, determined by One-Way ANOVA with Tukey correction for multiple comparisons.

3. Discussion

We have previously reported that β-Pro7-AngIII is a highly selective AT2R agonist that acutely evokes vasodilation and natriuresis [25,26]. However, the chronic effects of this AT2R agonist have not previously been described. In the present study, we report for the first time that β-Pro7-AngIII is anti-fibrotic and anti-inflammatory against HS-induced organ damage. These protective effects following AT2R activation were associated with reduced myofibroblast differentiation and TGF-β1 levels. Of note, this AT2R-selective peptide, at the dose that evoked anti-fibrotic and anti-inflammatory effects, did not affect blood pressure, indicating that the activation of AT2R directly contributes to cardio- and reno-protective effects, independent of systemic blood pressure.

Chronic HS intake has long been recognized as a major contributor to the development of CVDs globally [34,35]. A chronic HS diet induced cardiac and renal fibrosis in both hypertensive and normotensive animals [36–39]. Ferreira et al. reported that a HS diet (4%) significantly increased cardiac interstitial fibrosis in WKYs that was independent of blood pressure [36]. Similarly, we found that a HS diet (5%) increased cardiac and renal interstitial fibrosis in FVB/N mice without elevating blood pressure [40]. A HS diet increased cardiac and renal inflammation as well as fibrosis within 4–5 weeks [40–42]. In the current study, β-Pro7-AngIII was administered after the mice were already on a HS diet (5%) for 4 weeks; therefore, the ability of the novel AT2R-selective ligand to reverse established fibrosis was investigated, although we did not measure fibrosis directly after 4 weeks of HS diet in the current study. Impressively, β-Pro7-AngIII appeared to reverse the HS-induced fibrosis back to NS levels in both the heart and kidney, whereas these anti-fibrotic effects were blocked by the AT2R antagonist, PD123319, confirming that these anti-fibrotic effects induced by β-Pro7-AngIII were via AT2R activation. Consistent with the current findings, Patel et al. reported that chronic C21 treatment reduced HS-induced renal fibrosis in obese Zucker rats [43]. We have recently reported that the AT2R-selective peptide CGP4211 also reversed HS-induced fibrosis in the same model [40]. Therefore, our current findings are consistent with other evidence of AT2R-mediated anti-fibrotic effects in other disease models [21,22].
including reduced cardiac fibrosis following MI injury [44,45] and in SHR-SP [46] and reduced renal fibrosis in diabetic rodents [47,48] and SHR-SP [49].

TGF-β1-induced myofibroblast differentiation induces excessive collagen production and results in organ fibrosis [3–6]. As expected, we found that HS-induced organ fibrosis was closely related to increased TGF-β1 levels in the heart and kidney. Indeed, this increased myofibroblast differentiation in the heart would have contributed to the HS-induced cardiac fibrosis. While TGF-β1 activates Smad complexes that translocate across the nuclear membrane to regulate collagen gene expression directly [50], TGF-β1 also activates many other Smad-independent, pro-fibrotic pathways such as the extracellular signal-regulated kinase (ERK), c-Jun-N-terminal kinase (JNK) and p38 mitogen-activated protein kinase pathways [50] that may contribute to pathophysiological effects. In any case, consistent with the anti-fibrotic effects, β-Pro7-AngIII inhibited HS-induced cardiac and renal TGF-β1, as well as circulating TGF-β1 levels, which agrees well with the previous studies showing that AT2R stimulation inhibits TGF-β1 levels [40,44,47,51,52].

Chronic inflammation has been considered to be the primary trigger for fibrosis development [1,2]. HS-induced organ inflammation has been reported in many hypertensive animal models [53–55]. In the current study, we found that HS increased cardiac and renal inflammation (increased NF-κB activity and macrophage infiltration) in normotensive mice. Under these conditions, β-Pro7-AngIII reduced cardiac and renal inflammation, which was entirely consistent with an AT2R-mediated effect, as reported using other AT2R-selective agonists such as C21 and CGP42212 in other disease models [48,49,51,56–58]. The fact that PD123319 significantly inhibited the anti-fibrotic and anti-inflammatory effects caused by β-Pro7-AngIII in the majority of cases, or resulted in the combination treatment being not different from HS alone, confirmed the involvement of AT2R in the current study. The use of PD123319 to confirm an AT2R-mediated mechanism was necessary, particularly since a number of previous studies investigating the chronic effects of C21 did not include PD123319 [21].

In conclusion, we demonstrated that the novel AT2R-selective agonist β-Pro7-AngIII inhibited HS-induced cardiac and renal fibrosis and inflammation in a PD123319-sensitive manner. Collectively, these findings have established that the acute AT2R-mediated effects of this peptide [25] have translated into cardiac and renal anti-fibrotic and anti-inflammatory effects following chronic treatment with β-Pro7-AngIII. These findings further highlight the AT2R as a novel therapeutic target for the treatment of cardiac and renal diseases.

4. Materials and Methods

4.1. Materials

β-substituted angiotensin peptide synthesis, including β-Pro7-AngIII, had been described in detail previously [25,59]. PD123319 was purchased from Sigma-Aldrich (St. Louis, MO, USA).

4.2. Animals and Treatments

Male FVB/N mice aged from 10 to 12 weeks were obtained from the Monash Animal Research Precinct (Clayton, Victoria, Australia) and were housed in the Department of Pharmacology animal holding facility. All experimental procedures outlined below were approved by the Monash University Animal Ethics Committee (under MARP/2013/118). Mice were housed in standard mouse cages at 21 ± 3 °C, with a 12 h light/dark cycle with free access to food and water. Mice were fed with a HS diet (5% NaCl; SF05-038 diet containing 5% NaCl; Specialty Feeds Western Australia) for 4 weeks before drug administration. Thereafter, mice were randomized into treatment groups for another 4 weeks while on a HS diet and treatments were administered via mini osmotic pumps implanted subcutaneously. The randomized groups were: HS + saline, HS + β-Pro7-AngIII (0.1 mg/kg/day), or HS+ β-Pro7-AngIII (0.1 mg/kg/day) + PD123319 (1 mg/kg/day) from weeks 5–8. Another group of mice were fed with a normal salt (NS; 0.5% NaCl) diet for 8 weeks. All treatment groups were randomly allocated and investigators were blinded.
to treatments and subsequent analysis. The doses were chosen based on a similar dose of β-Pro7-AngII shown acutely to evoke vasodepressor effects in vivo [25].

4.3. Blood Pressure and Body Weight Measurements

Systolic blood pressure (SBP) was measured every 2 weeks, starting from week 0 (prior to HS diet) until week 8, using tail cuff plethysmography (MC4000 BP Analysis Systems; Hatteras Instruments Inc., Grantsboro, NC, USA). At least three cycles (with five measurements in each cycle) were performed and averaged for each animal at each time point. Body weight was measured every 2 weeks from week 0 (prior to HS diet) until week 8.

4.4. Analysis of Extracellular Matrix (ECM) and Inflammation

After week 8, mice were humanely killed by isoflurane overdose, and heart, kidneys and plasma were collected for ex vivo measurements. The left ventricle (LV) was separated into three portions; apex, mid-zone and base. One section from the mid-zone of the left ventricle (LV) and left kidney were embedded in OCT and immersed in methylbutane/isopentane (Merck) for slow freezing using liquid nitrogen. Next, 5 µm sections were cut using a Cryostat (Leica; CM1860) for both heart and kidney. Cardiac interstitial collagen deposition was identified from frozen sections that were stained with 0.05% picrosirius red (Polysciences Inc., Warrington, PA, USA). At the same time, a section from the mid-zone of the left kidney was fixed with 10% formalin for 24 h before picrosirius red staining (Monash Histology Platform).

Frozen cardiac and renal sections (5 µm) were used for immunofluorescence staining. Specific markers with relative antibody concentrations are summarized in Supplemental Table S1. All images were taken under 200 × magnification and quantified from an average of 6–8 fields of view for each heart and kidney section using Image J software.

The hydroxyproline content was also measured in both heart and kidney [52,60]. Equivalent tissue portions of kidney tissue (containing cortex and medulla) or left ventricular tissue (apical region) were lyophilized to dry weight, hydrolyzed in 6 M hydrochloric acid, and the collagen concentration was then calculated according to the hydroxyproline values [61].

4.5. Plasma TGF-β1 Measurement by ELISA

Plasma TGF-β1 levels were measured using a mouse TGF-β1 ELISA kit (R&D Systems; MB100B) according to the manufacturer’s specifications. TGF-β1 in plasma samples were activated by 1 N HCl followed by 1.2 N NaOH/0.5 M HEPES. A final dilution factor of 90 was applied in this assay as per the manufacturer’s instructions.

4.6. Statistical Analysis

All results were expressed as mean ± standard error of mean (s.e.m.). All statistical analyses were performed using the Prism program (GraphPad Prism software, version 9; San Diego, CA, USA). All statistical comparisons except SBP were conducted using One-Way analysis of variance (ANOVA) followed by Tukey’s post-hoc correction test for multiple comparisons between groups. SBP analysis was performed by two-way repeated measures ANOVA which allowed for within- and between-group analysis over time. For all results, p < 0.05 was deemed statistically significant.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms232214039/s1. Figure S1: Effect of systolic blood pressure; Table S1: Primary and secondary antibodies for immunofluorescence staining.
Author Contributions: The conceptualization for these experiments was conducted by R.E.W., Y.W., C.S.S. and K.M.D. The experiments were performed by Y.W., J.Y., I.S., L.N. and C.S.S.; the peptide was synthesized by M.D.B. and M.-I.A. and the analysis was performed by Y.W., R.E.W. and C.S.S. The original draft was prepared by Y.W., R.E.W. and C.S.S. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported in part by a National Health and Medical Research Council (NHMR) of Australia Project Grant to REW (GNT127792); and NHMR Senior Research Fellows to CSS (GNT1041766) and KMD (APP1041844).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data is available upon request. Contact Robert Widdop.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Prabh, S.D.; Frangogiannis, N.G. The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis. Circ. Res. 2016, 119, 91–112. [CrossRef]
2. Suthahar, N.; Meijers, W.C.; Sillje, H.H.W.; de Boer, R.A. From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities. Curr. Heart Fail. Rep. 2017, 14, 235–250. [CrossRef]
3. Bujak, M.; Frangogiannis, N.G. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc. Res. 2007, 74, 184–195. [CrossRef] [PubMed]
4. Huynh, P.; Chai, Z. Transforming growth factor beta (TGFbeta) and related molecules in chronic kidney disease (CKD). Clin. Sci. 2019, 133, 287–313. [CrossRef]
5. Tomasek, J.J.; Gabbiani, G.; Hinz, B.; Chapronnier, C.; Brown, R.A. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat. Rev. Mol. Cell. Biol. 2002, 3, 349–363. [CrossRef]
6. Schiller, M.; Javelaud, D.; Mauviel, A. TGF-beta-induced SMAD signaling and gene regulation: Consequences for extracellular matrix remodeling and wound healing. J. Dermatol. Sci. 2004, 35, 83–92. [CrossRef]
7. Wang, Y.; Wang, M.; Samuel, C.S.; Widdop, R.E. Preclinical rodent models of cardiac fibrosis. Br. J. Pharmacol. 2022, 179, 882–899. [CrossRef]
8. Bavishi, C.; Bangalore, S.; Messerli, F.H. Renin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction? Prog. Cardiovasc. Dis. 2016, 59, 253–261. [CrossRef]
9. van Vark, L.C.; Bertrand, M.; Akkerhuis, K.M.; Brugts, J.J.; Fox, K.; Mourad, J.J.; Boersma, E. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: A meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur. Heart J. 2012, 33, 2088–2097. [CrossRef]
10. Busche, S.; Gallinat, S.; Bohle, R.M.; Reinecke, A.; Seebeck, J.; Franke, F.; Fink, L.; Zhu, M.; Summers, C.; Unger, T. Expression of angiotensin AT(1) and AT(2) receptors in adult rat cardiomyocytes after myocardial infarction. A single-cell reverse transcriptase-polymerase chain reaction study. Am. J. Pathol. 2000, 157, 605–611. [CrossRef]
11. Nio, Y.; Matsubara, H.; Murasawa, S.; Kanasaki, M.; Inada, M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J. Clin. Investig. 1995, 95, 46–54. [CrossRef]
12. Ozono, R.; Wang, Z.Q.; Moore, A.F.; Inagami, T.; Siragy, H.M.; Carey, R.M. Expression of the subtype 2 angiotensin (AT2) receptor protein in rat kidney. Hypertension 1997, 30, 1238–1246. [CrossRef]
13. Cao, Z.; Kelly, D.J.; Cox, A.; Casley, D.; Forbes, J.M.; Martinello, P.; Dean, R.; Gilbert, R.E.; Cooper, M.E. Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int. 2000, 58, 2437–2451. [CrossRef] [PubMed]
14. Ruiz-Ortega, M.; Esteban, V.; Suzuki, Y.; Ruperez, M.; Mezzano, S.; Ardiles, L.; Justo, P.; Ortiz, A.; Egido, J. Renal expression of angiotensin type 2 (AT2) receptors during kidney damage. Kidney Int. 2003, 64 (Suppl. S86), S21–S26. [CrossRef]
15. Bautista, R.; Sanchez, A.; Hernandez, J.; Oyekan, A.; Escalante, B. Angiotensin II type AT(2) receptor mRNA expression and renal vasodilatation are increased in renal failure. Hypertension 2001, 38 Pt 2, 669–673. [CrossRef]
16. Esteban, V.; Lorenzo, O.; Ruperez, M.; Suzuki, Y.; Mezzano, S.; Blanco, J.; Kretzler, M.; Sugaya, T.; Egido, J.; Ruiz-Ortega, M. Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J. Am. Soc. Nephrol. 2004, 15, 1514–1529. [CrossRef]
17. Rigg, H.; de Gasparo, M.; Graedel, E.; Stulz, P.; Burkart, F.; Eberhard, M.; Erne, P. Angiotensin II-receptor subtypes in human atria and evidence for alterations in patients with cardiac dysfunction. Eur. Heart J. 1996, 17, 1112–1120. [CrossRef]
18. Tsutsumi, Y.; Matsubara, H.; Ohkubo, N.; Mori, Y.; Nozawa, Y.; Murasawa, S.; Kijima, K.; Maruyama, K.; Masaki, H.; Moriguchi, Y.; et al. Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Circ. Res. 1998, 83, 1035–1046. [CrossRef]
Goette, A.; Arndt, M.; Rocken, C.; Spiess, A.; Staack, T.; Geller, J.C.; Huth, C.; Ansorge, S.; Klein, H.U.; Lendeckel, U. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. *Circulation* 2000, 101, 2678–2681. [CrossRef]

Kaschina, E.; Namsolleck, P.; Unger, T. AT2 receptors in cardiovascular and renal diseases. *Pharmacol. Res.* 2017, 125 Pt A, 39–47. [CrossRef]

Wang, Y.; Del Borgo, M.; Lee, H.W.; Baraldi, D.; Hirmiz, B.; Gaspari, T.A.; Denton, K.M.; Aguilar, M.I.; Samuel, C.S.; Widdop, R.E. Anti-fibrotic Potential of AT2 Receptor Agonists. *Front. Pharmacol.* 2017, 8, 564. [CrossRef] [PubMed]

Summers, C.; Peluso, A.A.; Haugaard, A.H.; Bertelsen, J.B.; Steckelings, U.M. Anti-fibrotic mechanisms of angiotensin AT2-receptor stimulation. *Acta Physiol.* 2019, 227, e13280. [CrossRef] [PubMed]

Bosnyak, S.; Jones, E.S.; Christopoulos, A.; Aguilar, M.I.; Thomas, W.G.; Widdop, R.E. Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. *Clin. Sci.* 2011, 121, 297–303. [CrossRef] [PubMed]

Steer, D.L.; Lew, R.A.; Perlmuter, P.; Smith, A.I.; Aguilar, M.I. Beta-amino acids: Versatile peptidomimetics. *Curr. Med. Chem.* 2002, 9, 811–822. [CrossRef] [PubMed]

Del Borgo, M.; Wang, Y.; Bosnyak, S.; Khan, M.; Walters, P.; Spizzo, I.; Perlmuter, P.; Hilliard, L.; Denton, K.; Aguilar, M.I.; et al. beta-Pro7Ang III is a novel highly selective angiotensin II type 2 receptor (AT2R) agonist, which acts as a vasodepressor agent via the AT2R in conscious spontaneously hypertensive rats. *Clin. Sci.* 2015, 129, 505–513. [CrossRef]

Hilliard Krause, L.M.; Kemp, B.A.; Tan, A.S.J.; Jones, E.S.; Del Borgo, M.P.; Aguilar, M.I.; Denton, K.M.; Carey, R.M.; Widdop, R.E. Renal functional effects of the highly selective AT2R agonist, beta-Pro7 Ang III, in normotensive rats. *Clin. Sci.* 2020, 134, 871–884. [CrossRef] [PubMed]

Lattouf, R.; Younes, R.; Rutkowski, D.; Naaman, N.; Gedeon, G.; Senni, K.; Changotade, S. Picrosirius red staining: A useful tool to appraise collagen networks in normal and pathological tissues. *J. Histochim. Cytochem.* 2014, 62, 751–758. [CrossRef]

Samuel, C.S.; Unemori, E.N.; Mocke, J.; Bathgate, R.A.; Layfield, S.L.; Mak, J.; Tregear, G.W.; Du, X.J. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. *Endocrinology* 2004, 145, 4125–4133. [CrossRef]

Mack, M.; Yanagita, M. Origin of myofibroblasts and cellular events triggering fibrosis. *Kidney Int.* 2015, 87, 297–307. [CrossRef]

Liu, Y. Cellular and molecular mechanisms of renal fibrosis. *Nat. Rev. Nephrol.* 2011, 7, 684–696. [CrossRef]

Grande, M.T.; Lopez-Novoa, J.M. Fibroblast activation and myofibroblast generation in obstructive nephropathy. *Nat. Rev. Nephrol.* 2009, 5, 319–328. [CrossRef]

Leslie, K.O.; Taatjes, D.J.; Schwarz, J.; von Turkovich, M.; Low, R.B. Cardiac myofibroblasts express alpha smooth muscle actin during right ventricular pressure overload in the rabbit. *Am. J. Pathol.* 1991, 139, 207–216. [PubMed]

Desmouliere, A.; Geinoz, A.; Gabbiani, F.; Gabbiani, G. Transforming growth factor-beta1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. *J. Cell Biol.* 1993, 122, 103–111. [CrossRef] [PubMed]

O’Donnell, M.; Mente, A.; Yusuf, S. Sodium Intake and Cardiovascular Health. *Circ. Res.* 2015, 116, 1046–1057. [CrossRef]

Morrisson, A.C.; Ness, R.B. Sodium intake and cardiovascular disease. *Annu. Rev. Public Health* 2011, 32, 71–90. [CrossRef] [PubMed]

Ferreira, D.N.; Katayama, I.A.; Oliveira, I.B.; Rosa, K.T.; Furukawa, L.N.; Coelho, M.S.; Casarini, D.E.; Heimann, J.C. Salt-induced cardiac hypertrophy and interstitial fibrosis are due to a blood pressure-independent mechanism in Wistar rats. *J. Nutr.* 2010, 140, 1742–1751. [CrossRef]

Yu, H.C.; Burrell, L.M.; Black, M.J.; Wu, L.L.; Dilley, R.J.; Cooper, M.E.; Johnston, C.I. Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. *Circulation* 1998, 98, 2621–2628. [CrossRef]

Lal, A.; Veinot, J.P.; Leenen, F.H. Prevention of high salt diet-induced cardiac hypertrophy and fibrosis by spironolactone. *Am. J. Hypertens.* 2003, 16, 319–323. [CrossRef] [PubMed]

Grobe, J.L.; Mecca, A.P.; Mao, H.; Katovich, M.J. Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. *Am. J. Physiol. Heart Circ. Physiol.* 2006, 290, H2417-23. [CrossRef]

Wang, Y.; Han, L.; Shen, M.; Jones, E.S.; Spizzo, I.; Walton, S.L.; Denton, K.M.; Gaspari, T.A.; Samuel, C.S.; Widdop, R.E. Serelaxin and the AT2 Receptor Agonist CGP42112 Evoked a Similar, Nonadditive, Cardiac Antifibrotic Effect in High Salt-Fed Mice That Were Refractory to Candesartan Cilexetil. *Am. J. Pathol.* 2020, 189, H2417-23. [CrossRef]

Hijmans, R.S.; Shrestha, P.; Sarpong, K.A.; Yazdani, S.; El Masri, R.; de Jong, W.H.A.; Navis, G.; Vives, R.R.; van den Born, J. High sodium diet converts renal proteoglycans into pro-inflammatory mediators in rats. *PLoS ONE* 2017, 12, e0178940. [CrossRef] [PubMed]

Endemann, D.H.; Touyz, R.M.; Iglarz, M.; Savoia, C.; Schiffrin, E.L. Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. *Hypertension* 2004, 43, 1252–1257. [CrossRef] [PubMed]

Patel, S.N.; Ali, Q.; Samuel, P.; Steckelings, U.M.; Hussain, T. Angiotensin II Type 2 Receptor and Receptor Mas Are Colocalized and Functionally Interdependent in Obese Zucker Rat Kidney. *Hypertension* 2017, 70, 831–838. [CrossRef] [PubMed]

Lauer, D.; Slavic, S.; Sommerfeld, M.; Thone-Reineke, C.; Sharovsky, T.; Hallberg, A.; Dahlof, B.; Kintsch, U.; Unger, T.; Steckelings, U.M.; et al. Angiotensin type 2 receptor stimulation ameliorates left ventricular fibrosis and dysfunction via regulation of tissue inhibitor of matrix metalloproteinase 1/matrix metalloproteinase 9 axis and transforming growth factor beta1 in the rat heart. *Hypertension* 2014, 63, e60-7. [CrossRef]
45. Kaschina, E.; Grzesiak, A.; Li, J.; Foryst-Ludwig, A.; Rompe, F.; Sommerfeld, M.; Kemnitz, U.R.; Curato, C.; Namsolleck, P.; et al. Angiotensin II type 2 receptor stimulation: A novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? *Circulation* 2008, 118, 2523–2532. [CrossRef]

46. Rehman, A.; Leibowitz, A.; Yamamoto, N.; Rautureau, Y.; Paradis, P.; Schiffrin, E.L. Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. *Hypertension* 2012, 59, 291–299. [CrossRef]

47. Koulis, C.; Chow, B.S.; Steckelings, U.M.; Unger, T.; Thallas-Bonke, V.; Thomas, M.C.; Cooper, M.E.; Jandeleit-Dahm, K.A.; Allen, T.J. AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathy. *Hypertension* 2015, 65, 1073–1081. [CrossRef]

48. Castoldi, G.; di Gioia, C.R.; Bombardi, C.; Maestroni, S.; Carletti, R.; Steckelings, U.M.; Dahlof, B.; Unger, T.; Zerbini, G.; Stella, A. Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats. *Am. J. Physiol. Renal. Physiol.* 2014, 307, F1123-31. [CrossRef]

49. Gelosa, P.; Pignieri, A.; Fandriks, L.; de Gasparo, M.; Hallberg, A.; Banfi, C.; Castiglioni, L.; Turolo, L.; Guerrini, U.; Tremoli, E.; et al. Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: Focus on renal damage. *J. Hypertens.* 2009, 27, 2444–2451. [CrossRef]

50. Derynck, R.; Zhang, Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. *Nature* 2003, 425, 577–584. [CrossRef]

51. Matavelli, L.C.; Huang, J.; Siragy, H.M. Angiotensin AT(2) receptor stimulation inhibits early renal inflammation in renovascular hypertension. *Hypertension* 2011, 57, 308–313. [CrossRef] [PubMed]

52. Chow, B.S.; Kocan, M.; Bosnyak, S.; Sarwar, M.; Wigg, B.; Jones, E.S.; Widdop, R.E.; Summers, R.J.; Bathgate, R.A.; Hewitson, T.D.; et al. Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis. *Kidney Int.* 2014, 86, 75–85. [CrossRef] [PubMed]

53. Kain, D.; Amit, U.; Yagil, C.; Landa, N.; Naftali-Shani, N.; Molotski, N.; Aviv, V.; Feinberg, M.S.; Goitein, O.; Kushnir, T.; et al. Macrophages dictate the progression and manifestation of hypertensive heart disease. *Int. J. Cardiol.* 2016, 203, 381–395. [CrossRef]

54. Yang, G.H.; Zhou, X.; Ji, W.J.; Liu, J.X.; Sun, J.; Dong, Y.; Jiang, T.M.; Li, Y.M. VEGF-C-mediated cardiac lymphangiogenesis in high salt intake accelerated progression of left ventricular remodeling in spontaneously hypertensive rats. *Clin. Exp. Hypertens.* 2017, 39, 740–747. [CrossRef] [PubMed]

55. Behr, T.M.; Willette, R.N.; Coatney, R.W.; Berova, M.; Angermann, C.E.; Anderson, K.; Sackner-Bernstein, J.D.; Barone, F.C. Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattractant protein-1 and inflammation in hypertensive heart disease. *J. Hypertens.* 2004, 22, 583–592. [CrossRef] [PubMed]

56. Fatima, N.; Patel, S.; Hussain, T. Angiotensin AT2 Receptor is Anti-inflammatory and Reno-Protective in Lipopolysaccharide Mice Model: Role of IL-10. Role in renoprotection in obese rats. *Hypertension* 2013, 61, 1218–1226. [CrossRef] [PubMed]

57. Patel, S.; Dhande, I.; Gray, E.A.; Ali, Q.; Hussain, T. Prevention of lipopolysaccharide-induced CD11b(+) immune cell infiltration in the kidney: Role of AT(2) receptors. *Biosci. Rep.* 2019, 39, BS1904173. [CrossRef]

58. Fatima, N.; Patel, S.; Hussain, T. Angiotensin AT2 Receptor is Anti-inflammatory and Reno-Protective in Lipopolysaccharide Mice Model: Role of IL-10. *Front. Pharmacol.* 2021, 12, 600163. [CrossRef]

59. Jones, E.S.; Del Borgo, M.P.; Kirsch, J.F.; Clayton, D.; Bosnyak, S.; Welungoda, I.; Hausler, N.; Unabia, S.; Perlmuter, P.; Thomas, W.G.; et al. A single beta-amino acid substitution to angiotensin II confers AT2 receptor selectivity and vascular function. *Hypertension* 2011, 57, 570–576. [PubMed]

60. Chow, B.S.; Chew, E.G.; Zhao, C.; Bathgate, R.A.; Hewitson, T.D.; Samuel, C.S. Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: The additional involvement of iNOS. *PLoS ONE* 2012, 7, e42714. [CrossRef]

61. Hossain, M.A.; Samuel, C.S.; Binder, C.; Hewitson, T.D.; Tregeb, G.W.; Wade, J.D.; Bathgate, R.A. The chemically synthesized human relaxin-2 analog, B-R13/17K H2, is an RXFP1 antagonist. *Amino Acids* 2010, 39, 409–416. [CrossRef] [PubMed]